First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) Trading Up 1.4% - Here's What Happened

Key Points

• Trading move: LON:FBT rose 1.4% to GBX 1,897 on Friday but volume was extremely low — about 12 shares traded, a 99% drop from the average daily volume of 994.
• Valuation and technicals: The ETF has a market capitalization of £778.18 million, a deeply negative P/E of -1,724.55, and sits near its 50-day (GBX 1,845.75) and 200-day (GBX 1,861.88) simple moving averages.
• Editorial note: The article includes a company profile for Forbidden Technologies plc (Blackbird) that appears unrelated to the First Trust Biotechnology ETF, indicating a likely reporting error.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - )'s share price was up 1.4% on Friday . The stock traded as high as GBX 1,897 and last traded at GBX 1,897. Approximately 12 shares were traded during trading, a decline of 99% from the average daily volume of 994 shares. The stock had previously closed at GBX 1,871.60.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Up 1.4%

The stock has a market capitalization of £778.18 million and a price-to-earnings ratio of -1,724.55. The stock's 50-day simple moving average is GBX 1,845.75 and its 200 day simple moving average is GBX 1,861.88.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Company Profile

Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.